Skip to main content
. Author manuscript; available in PMC: 2022 Feb 26.
Published in final edited form as: J Vis Exp. 2019 Jan 25;(143):10.3791/58971. doi: 10.3791/58971

Figure 3: Doxorubicin induces DNA damage in human iPS cells.

Figure 3:

(A) DNA damage in doxorubicin-treated (Doxo) and nontreated (control) iPS cells, analyzed using the comet assay. (B) Fraction of DNA damage (n = 3) and (C) tail moment (n = 63 comets) quantified using the comet assay. Treatment with doxorubicin, a DNA-intercalating agent, significantly increased the fraction of DNA damage and tail moment in iPS cells. Data are means ± SEM. *P < 0.05, Student’s unpaired t-test.